[1]
2024. Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina. Biomolecules and Biomedicine. 24, 5 (Sep. 2024), 1400–1406. DOI:https://doi.org/10.17305/bb.2024.10433.